Myriad Genetics, Inc.
MYGN
$6.61
-$0.18-2.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.78% | -6.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.78% | -6.98% | |||
| Cost of Revenue | -0.65% | 3.35% | |||
| Gross Profit | 13.11% | -11.07% | |||
| SG&A Expenses | 2.21% | -0.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.31% | -1.32% | |||
| Operating Income | 56.90% | -67.63% | |||
| Income Before Tax | -1,024.49% | 24.81% | |||
| Income Tax Expenses | 99.66% | -961.76% | |||
| Earnings from Continuing Operations | -330,400.00% | 99.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -330,400.00% | 99.76% | |||
| EBIT | 56.90% | -67.63% | |||
| EBITDA | 110.96% | -484.00% | |||
| EPS Basic | -324,718.18% | 99.76% | |||
| Normalized Basic EPS | 53.28% | -92.71% | |||
| EPS Diluted | -324,718.18% | 99.77% | |||
| Normalized Diluted EPS | 53.28% | -92.71% | |||
| Average Basic Shares Outstanding | 1.20% | 0.33% | |||
| Average Diluted Shares Outstanding | 1.20% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||